title: XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
abstract: This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.
authors: a Department of Gastrointestinal Surgery , First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
authors: Yu
authors: Y
authors: Guo
authors: b Department of Gastrointestinal and Hernia Surgery , First Affiliated Hospital of Kunming Medical University, No. 1 School of Clinical Medicine, Kunming Medical University , Kunming , China.
authors: Bing-Hong
authors: BH
authors: Xiong
authors: c Department of Oncology , First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
authors: Tao
authors: T
authors: Zhang
authors: a Department of Gastrointestinal Surgery , First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
authors: Yong
authors: Y
authors: Cheng
authors: d Department of Emergency , the Third Hospital of Mianyang , Mianyang , China.
authors: Li
authors: L
authors: Ma
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D016017:Odds Ratio; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010071:Oxaloacetates; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil
keywords: Capecitabine; Colorectal cancer; Fluorouracil; Oxaliplatin